- Home
- EYPT vs NAC Comparison
EYPT vs NAC Comparison
Compare EYPT & NAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | NAC |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | EYPT | NAC |
|---|---|---|
| Price | $13.35 | $11.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 307.3K |
| Earning Date | 03-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,339,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.91 | $9.32 |
| 52 Week High | $19.11 | $11.21 |
Technical Indicators
Market Signals| Indicator | EYPT | NAC |
|---|---|---|
| Relative Strength Index (RSI) | 36.20 | 46.16 |
| Support Level | $12.11 | $11.79 |
| Resistance Level | $13.68 | $11.99 |
| Average True Range (ATR) | 0.99 | 0.08 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 23.16 | 35.42 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.